Skip to main content

Month: September 2025

Construction contract (Commercial building in Narva)

AS Nordecon group company Embach Ehitus OÜ and Kaarsilla Kinnisvara OÜ entered into a contract for the construction of a commercial building in Narva, Kreenholmi 54A. The total cost of the contract is 5.05 million euros excluding VAT, and the works will be completed in July 2026. Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Ukraine and Sweden. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2024 was 224 million euros. Currently Nordecon Group employs close to 420 people. Since 18 May 2006 the company’s shares have been quoted in the main list of the Nasdaq...

Continue reading

Consumers under 40 are skipping life insurance as they delay traditional triggers such as marriage and parenthood

Capgemini Press contact:  Fahd Pasha  Tel.: +1 647 860 3777                          E-mail: Fahd.Pasha@capgemini.com LIMRA Press contact: Catherine Theroux Tel.: +1 (860) 285-7787 E-mail: ctheroux@limra.com                        Consumers under 40 are skipping life insurance as they delay traditional triggers such as marriage and parenthoodUnder-40 consumers overlook traditional life insurance plans citing misalignment with their stage in life (32%), high costs of premiums (28%), and lack of immediate benefits (25%) Majority seek living benefits instead, like emergency financial support, wellness rewards or coverage for fertility treatmentsParis and Windsor, CT, September 15, 2025 – The World Life Insurance Report 2026, conducted jointly by the Capgemini Research Institute and LIMRA, shows that even though 68% of adults under the...

Continue reading

MMC Announces First Gold Pour Completed at the Bayan Khundii Mine in Mongolia

On Track for Nameplate Capacity Production in Q4 2025 HONG KONG, Sept. 14, 2025 (GLOBE NEWSWIRE) — Mongolian Mining Corporation (“MMC” or the “Company”, or together with its subsidiaries, the “Group”; HKEx: 975; OTCQX: MOGLF), the largest internationally listed private mining company with operations focused on and located in Mongolia, is pleased to announce the successful completion of the first gold pour at the Bayan Khundii (“BKH”) gold mine in Mongolia on 14 September 2025. The BKH gold mine has a total gold reserve of 513,700 ounces at an average head grade of 4.0 g/t gold, the mine is expected to produce approximately 85,000 ounces of gold per annum at a low quartile all-in sustaining cost. The Group announced its investment of US$40 million for 50% equity interest in Erdene Mongol LLC (“EM”), under a Strategic Alliance and...

Continue reading

Alamos Gold Announces the Sale of its Turkish Development Projects for Total Cash Consideration of $470 million

All amounts are in United States dollars, unless otherwise stated. TORONTO, Sept. 14, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (together with its direct and indirect subsidiaries, “Alamos” or the “Company”) today announced that its wholly owned Netherlands subsidiaries, Alamos Gold Holdings Coöperatief U.A. and Alamos Gold Holdings B.V. (the “Netherlands Subsidiaries”), have entered into a definitive agreement to sell Doğu Biga Madencilik Sanayi ve Tic. A.Ş., their wholly owned Turkish subsidiary, which owns the Kirazlı, Ağı Dağı and Çamyurt projects located in northwestern Türkiye, to Tümad Madencilik Sanayi ve Ticaret A.Ş (“Tümad”), a mining company operating in the Republic of Türkiye, for total cash consideration of $470 million (the “Purchase Price”) (the “Transaction”). The Purchase Price is payable by...

Continue reading

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Officially Started the Spinoff Plan for the Crypto Flywheel, a Second Independently Listed Company, to be Named CXC10

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Officially Started the Spinoff Plan for the Crypto Flywheel, a Second Independently Listed Company, to be Named CXC10Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Officially Started the Spinoff Plan for the Crypto Flywheel, a Second Independently Listed Company, to be Named CXC10The Company’s 919 event is just 5 days away. Company updates will be given at the 919 event including details on C10 & C (Crypto), the Company’s three growth engines, including the C10 Treasury; its roadmap for capital value realization; and the deployment strategy for FF EAI Vehicle Chain products.LOS ANGELES, Sept. 14, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”),...

Continue reading

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York. Mesoblast Chief Executive Silviu Itescu reiterated the strong first quarter launch of Ryoncil® and product sales in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD) as recently reported in the Company’s full year earnings and discussed the continued drive to onboard new sites and increase product...

Continue reading

AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe

VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialize RECELL GO in Europe and in other markets that recognize the CE Mark. “CE Mark for RECELL® GO is an important milestone for AVITA Medical and for patients,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “It enables us to bring this option to burn centers and clinicians in Europe to support their treatment of patients with acute wound injuries.” RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells (Spray-On Skin™...

Continue reading

Fangzhou Unveils “XingShi” LLM to Advance AI-Driven Chronic Disease Management

SHANGHAI, Sept. 14, 2025 (GLOBE NEWSWIRE) — At its 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced the release of its proprietary “XingShi” Large Language Model (“XS LLM”), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians’ available time. XS LLM integrates multimodal capabilities — image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning — while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: “AI Knowledge Agent”, “AI Guidance Agent”, “AI...

Continue reading

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan. Monopar’s poster presentation is available at the following link: https://www.monopartx.com/ALXN1840-ANA-2025-Poster-14-Sep-2025. The...

Continue reading

Subsea7 awarded contract offshore Saudi Arabia

Luxembourg – 14 September 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a major1 project under the long-term agreement (LTA) with Aramco that relates to certain facilities located offshore Saudi Arabia. The contract scope includes the engineering, procurement, construction, and installation (EPCI) of 106 kilometres of infield and export pipelines, modification to existing topsides, and associated hook-up activities. Project management and engineering work will begin immediately at Subsea7’s offices in Saudi Arabia and the UAE. Offshore activities are scheduled for 2027 and 2028. David Bertin, Senior Vice President for Subsea7 Global Projects Centre East, said: “This project marks another important milestone and reinforces our long-term strategic engagement with Aramco. We look forward to working...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.